- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07755475
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels
This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.
Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89101
- Citruslabs
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Be male or female.
- Be aged 25-60.
- Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
- difficulty concentrating or low mental sharpness
- experiences of brain fog or lack of mental clarity
- feeling of low productivity
- muscle weakness
- unwanted food cravings.
- Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
- Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
- Anyone with a BMI 18.5 to 30.
- Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Anyone willing to maintain a consistent diet and physical activity throughout study duration.
Exclusion Criteria:
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
- Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
- Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
- Anyone taking antibiotics.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone with a history of substance abuse.
- Anyone who is a shift worker with an irregular sleep-wake cycle.
- Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Anyone who is currently a smoker or has been a smoker in the past 3 months.
- Currently partaking in another research study, or planning to at any point during this study's duration.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Cellular Hydration Supplement
|
All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Cognitive Battery Test Score (Polygons)
Ramy czasowe: Baseline and Week 4
|
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Double Trouble)
Ramy czasowe: Baseline and Week 4
|
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Feature Match)
Ramy czasowe: Baseline and Week 4
|
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Paired Associates)
Ramy czasowe: Baseline and Week 4
|
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Digit Span)
Ramy czasowe: Baseline and Week 4
|
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
|
Baseline and Week 4
|
|
Change in Cognitive Battery Test Score (Spatial Planning)
Ramy czasowe: Baseline and Week 4
|
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
|
Baseline and Week 4
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Self-Reported Mental Clarity and Focus
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Alertness
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Mood
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Physical Performance
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Overall Energy Levels
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
|
Change in Self-Reported Frequency of Food Cravings
Ramy czasowe: Baseline, Week 1, Week 2, Week 3, and Week 4
|
Assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 3, and Week 4
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 20772
- legacy-20772
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .